CODX
Co-Diagnostics, Inc.Company Information
- Company Name
- Co-Diagnostics, Inc.
- CIK
- CIK0001692415
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CODX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- CODX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-03-20
- Last sale
- 2021-09-08
- Shares purchased (TTM)
- 3,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 578,214
- Shares outstanding
- 4,309,997
- Ownership
- 13.42%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -22.15%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 8 | 12 | 11 | 11 | 2 | 3 | 11 | 14 | 23 | 15 | 10 | ||||||
| Marketable Securities Current | - | - | - | - | 2 | 20 | 27 | 27 | 31 | 27 | 44 | 53 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | ||||||
| Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 5 | ||||||
| Income Tax Receivable | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Income Taxes Receivable | 0 | 0 | 0 | 1 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | ||||||
| Notes And Loans Receivable Net Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets Current | 5 | 10 | 14 | 14 | 15 | 24 | 32 | 40 | 48 | 54 | 62 | 71 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Intangible Assets Net Excluding Goodwill | 7 | 7 | 7 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | ||||||
| Real Estate Investments Joint Ventures | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | - | 1 | - | ||||||
| Assets | 17 | 21 | 25 | 45 | 46 | 55 | 64 | 72 | 81 | 87 | 95 | 109 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Asset Acquisition Contingent Consideration Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 3 | 4 | 4 | 4 | 4 | 5 | 7 | 6 | 5 | 5 | 6 | 5 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Asset Acquisition Contingent Consideration Liability Noncurrent | - | - | - | - | - | 0 | 0 | 1 | 1 | 0 | 1 | 0 | ||||||
| Liabilities Noncurrent | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | ||||||
| Liabilities | 4 | 5 | 4 | 5 | 5 | 7 | 10 | 9 | 8 | 8 | 9 | 9 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -16 | -16 | -16 | -16 | -16 | -16 | -16 | -16 | -16 | -16 | -16 | -15 | ||||||
| Additional Paid In Capital | 124 | 121 | 117 | 109 | 105 | 104 | 102 | 101 | 100 | 98 | 97 | 95 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -96 | -90 | -80 | -54 | -48 | -41 | -33 | -22 | -12 | -5 | 5 | 19 | ||||||
| Stockholders Equity | 13 | 16 | 21 | 40 | 41 | 47 | 54 | 64 | 72 | 78 | 86 | 99 | ||||||
| Liabilities And Stockholders Equity | 17 | 21 | 25 | 45 | 46 | 55 | 64 | 72 | 81 | 87 | 95 | 109 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 5 | 4 | 30 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 5 | 4 | 30 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCo-Diagnostics, Inc. (CODX) — SEC Financial Statements & Analysis
Co-Diagnostics, Inc. (CODX) is a surgical & medical instruments & apparatus company, incorporated in UT. Co-Diagnostics, Inc. trades on Nasdaq as: CODX. Co-Diagnostics, Inc. (CODX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Co-Diagnostics, Inc. carries a market cap of $13.36M, a P/E ratio of -0.28x, a P/B ratio of 1.05x, a P/S ratio of 18.52x, an enterprise value of $9.71M, and an EV/EBITDA multiple of -0.20x. On profitability, it posts a gross margin of 43.48%, an operating margin of -6787.59%, a net margin of -6523.04%, a Return on Equity (ROE) of -176.19%, a Return on Assets (ROA) of -149.25%, and a Return on Invested Capital (ROIC) of -244.73%. Per share, it reports EPS of $-10.92, diluted EPS of $-10.92, free cash flow per share of $-6.37, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -28.12% year-over-year, net income growth of 30.74% year-over-year, and EPS growth of -66.52% year-over-year. On the balance sheet, it maintains a current ratio of 1.81x, a quick ratio of 1.29x, working capital of $2.33M, a debt-to-equity ratio of 0.31x, a debt ratio of 0.23, free cash flow of $-27.47M (TTM), and net debt of $-3.65M. Figures sourced from SEC EDGAR.
- Market Cap
- $13.36M
- P/E TTM
- -0.28x
- EPS TTM
- $-10.92
- P/B TTM
- 1.05x
- ROE TTM
- -176.19%
- ROA TTM
- -149.25%
- Debt To Equity
- 0.31x
- Free Cash Flow TTM
- $-27.47M
- Net Revenue TTM Growth 1Y
- -28.12%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Co-Diagnostics, Inc. in?
Co-Diagnostics, Inc. (CODX) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does CODX trade on?
Co-Diagnostics, Inc. (CODX) trades on the Nasdaq.
Where is Co-Diagnostics, Inc. incorporated?
Co-Diagnostics, Inc. is incorporated in UT.
When was Co-Diagnostics, Inc. (CODX)'s most recent SEC filing?
Co-Diagnostics, Inc. (CODX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CODX's market cap?
Co-Diagnostics, Inc. (CODX) has a market capitalization of $13.36M as of 2026-06-30.
What is CODX's EPS (earnings per share)?
Co-Diagnostics, Inc. (CODX)'s trailing twelve month EPS is $-10.92 as of 2026-06-30.
What is CODX's ROE (return on equity)?
Co-Diagnostics, Inc. (CODX)'s trailing twelve month Return on Equity (ROE) is -176.19% as of 2026-06-30.
What is CODX's ROA (return on assets)?
Co-Diagnostics, Inc. (CODX)'s trailing twelve month Return on Assets (ROA) is -149.25% as of 2026-06-30.
What is CODX's ROIC (return on invested capital)?
Co-Diagnostics, Inc. (CODX)'s trailing twelve month Return on Invested Capital (ROIC) is -244.73% as of 2026-06-30.
What is CODX's EV/EBITDA?
Co-Diagnostics, Inc. (CODX)'s trailing twelve month EV/EBITDA is -0.20x as of 2026-06-30.